IL-4 receptor α polymorphisms are predictors of a pharmacogenetic response to a novel IL-4/IL-13 antagonist.
作者信息
Slager Rebecca E, Hawkins Gregory A, Ampleford Elizabeth J, Bowden Alexandra, Stevens Lauren E, Morton Matthew T, Tomkinson Adrian, Wenzel Sally E, Longphre Malinda, Bleecker Eugene R, Meyers Deborah A
出版信息
J Allergy Clin Immunol. 2010 Oct;126(4):875-8. doi: 10.1016/j.jaci.2010.08.001.
Abstract
摘要
相似文献
1
IL-4 receptor α polymorphisms are predictors of a pharmacogenetic response to a novel IL-4/IL-13 antagonist.
J Allergy Clin Immunol. 2010 Oct;126(4):875-8. doi: 10.1016/j.jaci.2010.08.001.
2
IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor α antagonist.
J Allergy Clin Immunol. 2012 Aug;130(2):516-22.e4. doi: 10.1016/j.jaci.2012.03.030. Epub 2012 Apr 26.
3
Pitrakinra for asthma.
Expert Opin Biol Ther. 2010 Nov;10(11):1609-15. doi: 10.1517/14712598.2010.524203. Epub 2010 Oct 5.
4
Inhaled vs subcutaneous effects of a dual IL-4/IL-13 antagonist in a monkey model of asthma.
Allergy. 2010 Jan;65(1):69-77. doi: 10.1111/j.1398-9995.2009.02156.x. Epub 2009 Oct 1.
5
Hexamethylene diisocyanate asthma is associated with genetic polymorphisms of CD14, IL-13, and IL-4 receptor α.
J Allergy Clin Immunol. 2011 Aug;128(2):418-20. doi: 10.1016/j.jaci.2011.03.007. Epub 2011 Apr 13.
6
[Single nucleotide polymorphism in asthma predisposing genes in children in Shanghai].
Zhonghua Er Ke Za Zhi. 2009 Apr;47(4):303-4.
7
An update on emerging drugs for asthma.
Expert Opin Emerg Drugs. 2012 Mar;17(1):37-42. doi: 10.1517/14728214.2012.657625. Epub 2012 Jan 31.
8
Anti-IL-4/-13 based therapy in asthma.
Expert Opin Emerg Drugs. 2015 Sep;20(3):349-52. doi: 10.1517/14728214.2015.1050377. Epub 2015 Jun 1.
9
A Critical Evaluation of Anti-IL-13 and Anti-IL-4 Strategies in Severe Asthma.
Int Arch Allergy Immunol. 2016;170(2):122-31. doi: 10.1159/000447692. Epub 2016 Aug 3.
10
[Inflammatory cytokines (IL-4, IL-5 and IL-13)].
Nihon Rinsho. 2001 Oct;59(10):1894-9.
引用本文的文献
1
Diagnostic value of bronchoprovocation challenge with adenosine monophosphate versus exercise testing in early diagnosis of asthma.
Med J Armed Forces India. 2021 Jan;77(1):46-50. doi: 10.1016/j.mjafi.2019.12.002. Epub 2020 Mar 21.
2
Preclinical characterization of the ADME properties of a surrogate anti-IL-36R monoclonal antibody antagonist in mouse serum and tissues.
MAbs. 2020 Jan-Dec;12(1):1746520. doi: 10.1080/19420862.2020.1746520.
3
Pharmacogenetic Factors Affecting Asthma Treatment Response. Potential Implications for Drug Therapy.
Front Pharmacol. 2019 May 21;10:520. doi: 10.3389/fphar.2019.00520. eCollection 2019.
4
Immune monitoring for precision medicine in allergy and asthma.
Curr Opin Immunol. 2017 Oct;48:82-91. doi: 10.1016/j.coi.2017.08.007. Epub 2017 Sep 7.
5
New perspectives on the regulation of type II inflammation in asthma.
F1000Res. 2017 Jun 28;6:1014. doi: 10.12688/f1000research.11198.1. eCollection 2017.
6
IL-4 Haploinsufficiency Specifically Impairs IgE Responses against Allergens in Mice.
J Immunol. 2017 Mar 1;198(5):1815-1822. doi: 10.4049/jimmunol.1601434. Epub 2017 Jan 23.
7
Toward precision medicine and health: Opportunities and challenges in allergic diseases.
J Allergy Clin Immunol. 2016 May;137(5):1289-300. doi: 10.1016/j.jaci.2016.03.006.
8
Genetics of asthma: an introduction for the clinician.
Eur Clin Respir J. 2015 Jan 16;2. doi: 10.3402/ecrj.v2.24643. eCollection 2015.
9
IL-4 and IL-13 signaling in allergic airway disease.
Cytokine. 2015 Sep;75(1):68-78. doi: 10.1016/j.cyto.2015.05.014. Epub 2015 Jun 9.
10
Novel targeted therapies for eosinophil-associated diseases and allergy.
Annu Rev Pharmacol Toxicol. 2015;55:633-56. doi: 10.1146/annurev-pharmtox-010814-124407. Epub 2014 Oct 17.
本文引用的文献
1
Inhaled vs subcutaneous effects of a dual IL-4/IL-13 antagonist in a monkey model of asthma.
Allergy. 2010 Jan;65(1):69-77. doi: 10.1111/j.1398-9995.2009.02156.x. Epub 2009 Oct 1.
2
Pathogenicity of a disease-associated human IL-4 receptor allele in experimental asthma.
J Exp Med. 2009 Sep 28;206(10):2191-204. doi: 10.1084/jem.20091480. Epub 2009 Sep 21.
3
Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies.
Lancet. 2007 Oct 20;370(9596):1422-31. doi: 10.1016/S0140-6736(07)61600-6.
4
IL4R alpha mutations are associated with asthma exacerbations and mast cell/IgE expression.
Am J Respir Crit Care Med. 2007 Mar 15;175(6):570-6. doi: 10.1164/rccm.200607-909OC. Epub 2006 Dec 14.
5
IL-4/IL-13 pathway genetics strongly influence serum IgE levels and childhood asthma.
J Allergy Clin Immunol. 2006 Feb;117(2):269-74. doi: 10.1016/j.jaci.2005.10.024.
6
Genetics of IL-13 and functional relevance of IL-13 variants.
Curr Opin Allergy Clin Immunol. 2002 Oct;2(5):389-93. doi: 10.1097/00130832-200210000-00004.
7
Gene-gene interaction in asthma: IL4RA and IL13 in a Dutch population with asthma.
Am J Hum Genet. 2002 Jan;70(1):230-6. doi: 10.1086/338242. Epub 2001 Nov 14.
8
Identification and association of polymorphisms in the interleukin-13 gene with asthma and atopy in a Dutch population.
Am J Respir Cell Mol Biol. 2001 Sep;25(3):377-84. doi: 10.1165/ajrcmb.25.3.4483.
9
The association of atopy with a gain-of-function mutation in the alpha subunit of the interleukin-4 receptor.
N Engl J Med. 1997 Dec 11;337(24):1720-5. doi: 10.1056/NEJM199712113372403.
Zotero 插件